about
C-X-C motif chemokine receptor 5Heat shock protein 1 (chaperonin)Interleukin 4Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit deltaMembrane-spanning 4-domains, subfamily A, member 1CD86 antigenChemokine (C-X-C motif) receptor 5Zeta chain of T cell receptor associated protein kinase 70Interleukin 4Bone marrow stromal cell antigen 2Fc receptor like 1A-kinase anchoring protein 17ALymphocyte transmembrane adaptor 1CD79a moleculeGRB2 binding adaptor protein, transmembraneCholinergic receptor nicotinic beta 2 subunitCholinergic receptor, nicotinic, alpha polypeptide 7MALT1 paracaspaseProtein kinase C betaTaxilin alphaIKAROS family zinc finger 3Immunoglobulin binding protein 1Src kinase associated phosphoprotein 2Linker for activation of T cells family member 2B cell scaffold protein with ankyrin repeats 1CD40 moleculeHistone deacetylase 4B cell linkerHistone deacetylase 9Cholinergic receptor nicotinic alpha 4 subunitIcos ligandImmunoglobulin-binding protein 1bMALT1 paracaspaseHistone deacetylase 7CD79A antigen (immunoglobulin-associated alpha)CD40 antigenProtein kinase C, betaB cell linkerComplement receptor type 2Cholinergic receptor, nicotinic, alpha polypeptide 4
P682
Cloning and sequencing of a trophoblast-endothelial-activated lymphocyte surface protein: cDNA sequence and genomic structureFcRH1: an activation coreceptor on human B cells.RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics.RASGRP1 mutation in autoimmune lymphoproliferative syndrome-like disease.The B cell surface molecule B1 is functionally linked with B cell activation and differentiation
P921
Q1024612-EA7DBBFB-AFBF-4693-A247-82CB07989996Q14865001-0C3D2BED-DCE1-48D8-BB62-ABD2CB497163Q14865001-4547D39C-0CAC-47C7-A11F-92B3498486E5Q14865961-2E9DD888-29B9-4C49-9F63-3A246CCB8CFFQ14865961-7A1C8447-590A-457C-B3D4-64FB636A485EQ14887753-6A37A881-E774-467A-986C-4EAFB7848487Q14906103-6571F49E-768D-4C40-9ECC-A285E8373B16Q14906103-F74F900D-BEA2-4C02-A969-CE3EFCBA23D0Q14907532-314E1D9B-4A00-436A-AFE5-485CCB73EA71Q14911992-094DC174-EC11-4BAA-A291-EF9B8487A49DQ1998562-B0E6E48A-6D6E-4AE5-BA35-5A2C9980E552Q2007868-16D7BB9E-24D5-44CC-A987-671AD79D49B4Q21100505-6D72F9A2-2B23-4A37-9AFA-61E8DDF0430DQ21101430-9DC22FA9-2213-4227-879C-EDF31C3A0472Q21105071-0B0844AE-7FEF-4500-82D3-BECDE0875006Q21106231-50005F86-5919-40AB-829F-864C95581ABCQ21109689-8F25F472-1E24-435D-AE66-90AD04D1B0FBQ21110316-A3EB048A-8B76-42E6-A532-934E36E30DEFQ21111171-A0D45A75-1643-4E24-B5E8-23E5F5E11412Q21111177-8CA02207-7231-40B2-8775-A5D40C709BA9Q21113910-2F748EAB-6879-4E9B-A58A-EF8D084CB5C6Q21114850-42859FA2-BD35-461E-84C5-55F2984EEC69Q21115054-28081188-410C-46A8-B104-7BB7F77426B1Q21115201-0DE81F59-EB97-4F6F-B018-F73B5A8E03FBQ21118373-2A6F2CE8-75E0-433A-9D0E-E13415438AB8Q21120489-DD053A0D-7CEC-4FCA-AE72-FDA0410AE474Q21123170-0ADAAA32-0188-4A52-9630-00B42452838CQ21132760-18076911-7E56-41EC-84D4-16FDF251E893Q21132760-DF4707EB-7B67-4141-BECC-B5A8E000B60BQ21135811-E0C5A269-4537-405A-A262-0C62F24FC2FFQ21173206-860F887E-FC7C-49F9-A98F-29D87CB1EE77Q21173210-2ACB97E7-D249-499D-ABCA-B4FAAB6F7031Q21173427-D2007872-8433-4290-8056-AF00DCBC0EDFQ21201618-99F0AA3F-394D-4791-8096-BCC9DA8CB456Q21245935-E1EC3DA5-83A6-4BB2-A5D6-8F3A22E15F66Q21433672-62188838-16D8-4309-886D-1EA9B1F324F6Q21436535-30673E1F-53F0-4A2F-9739-B979F50BD589Q21436535-B1726103-50C6-4E35-9D4A-921A705D91BDQ21491059-131AF871-0468-4071-B084-5435F20095BFQ21494044-EF7D59A4-40D1-4929-8A9A-4A43B4D28D1D
P682
description
The change in morphology and b ...... igen for which it is specific.
@en
biologisch proces
@nl
name
B cell activation
@en
B-celleaktivering
@nn
type
label
B cell activation
@en
B-celleaktivering
@nn
altLabel
B lymphocyte activation
@en
B-cell activation
@en
B-lymfocyttaktivering
@nn
B-lymphocyte activation
@en
B-selleaktivering
@nn
GO:0042113
@en
GO:0042113
@nn
prefLabel
B cell activation
@en
B-celleaktivering
@nn
P2888
P686
GO:0042113